Streptozotocin in advanced small cell bronchogenic carcinoma: an ineffective nonmyelosuppressive agent.
Thirteen patients with advanced small cell bronchogenic carcinoma (SCBC) received at least three weekly cycles of iv streptozotocin (STZ). There were no objective responses. Four patients progressed by the third week of therapy and an additional eight by the fourth week. Toxicity was acceptable especially in view of the extensive prior therapy. STZ is unlikely to be of benefit in combination chemotherapy regiments for SCBC.